PMID- 30196323
OWN - NLM
STAT- MEDLINE
DCOM- 20190218
LR  - 20190219
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 37
IP  - 11
DP  - 2018 Nov
TI  - Febuxostat in the treatment of gout patients with low serum uric acid level: 
      1-year finding of efficacy and safety study.
PG  - 3107-3113
LID - 10.1007/s10067-018-4283-z [doi]
AB  - To retrospectively analyze the efficacy and safety of febuxostat on gout patients 
      with low serum uric acid level. A study was conducted in Nanjing First Hospital 
      from October 2015 to September 2016. Thirty nine acute gouty arthritis patients 
      from the emergency and outpatient department were included. Patients met the 2015 
      Gout Classification Criteria revised by American College of Rheumatology/European 
      League Against Rheumatism (ACR/EULAR) and had urate deposition around the joints 
      detected by dual-energy computerized tomography (DECT). Patients whose serum uric 
      acid (SUA) were between 5.0 and 7.0 mg/dl (300-420 mumol/l) received febuxostat 
      treatment to maintain the SUA level between 3.0 and 5.0 mg/dl for 1 year. 
      Efficacy and safety of febuxostat were observed during the process. Three of 39 
      subjects were excluded because of adverse events (AEs) after receiving an initial 
      febuxostat treatment for 2 months. Thirty six subjects were enrolled. The mean 
      SUA level was reduced significantly from 6.51 +/- 0.28 mg/dl at baseline to 
      4.24 +/- 0.38 mg/dl and SUA of all subjects decreased by 34.8% compared with 
      baseline. After 1-year treatment, the volume of tophus was reduced approximately 
      62.8%. Serum creatinine decreased stepwise in 8 gout patients with chronic kidney 
      diseases from 162.5 +/- 9.2 mumol/l to 131.4 +/- 11.0 mumol/l. Two months after 
      initiation of treatment, the number of gout flares began to markedly decrease and 
      almost did not occur after 1 year. After the 1-year treatment of febuxostat, the 
      average SUA level declined significantly, and the renal function improved 
      gradually. There was nearly complete abolition of gout flares by the end of the 
      study. Tophi resolved markedly compared with baseline as assessed by DECT. 
      Furthermore, only a few people experienced adverse events. Febuxostat has a 
      notable effect for gout patients in the lower SUA level range.
FAU - Shen, Minning
AU  - Shen M
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Zhang, Junyu
AU  - Zhang J
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Qian, Kai
AU  - Qian K
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Li, Chunmei
AU  - Li C
AD  - Department of Clinical Laboratory, Changzhou traditional Chinese Medicine 
      Hospital, Changzhou, 213000, China.
FAU - Xu, Wenyu
AU  - Xu W
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Gu, Bingjie
AU  - Gu B
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Wang, Xiaoqin
AU  - Wang X
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Ren, Qijie
AU  - Ren Q
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Yang, Leilei
AU  - Yang L
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Yuan, Hai
AU  - Yuan H
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Su, Dinglei
AU  - Su D
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China.
FAU - Chen, Xingguo
AU  - Chen X
AUID- ORCID: 0000-0001-6623-7703
AD  - Department of Rheumatology and Immunology, Nanjing First Hospital, Nanjing 
      Medical University, Nanjing, 210006, China. 13851750676@163.com.
LA  - eng
GR  - QRX11026/the Key Programs of Medical Science and Technology Development 
      Foundation of the Nanjing Department of Health/
GR  - 2014NJMU047/Science and Technology Development Foundation of Nanjing Medical 
      University/
PT  - Journal Article
PT  - Observational Study
DEP - 20180909
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Gout Suppressants)
RN  - 101V0R1N2E (Febuxostat)
RN  - 268B43MJ25 (Uric Acid)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Aged
MH  - Arthritis, Gouty/*drug therapy
MH  - Creatinine/blood
MH  - Febuxostat/adverse effects/*therapeutic use
MH  - Female
MH  - Gout/blood/*drug therapy
MH  - Gout Suppressants/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Uric Acid/*blood
OTO - NOTNLM
OT  - Efficacy
OT  - Febuxostat
OT  - Gout
OT  - Safety
OT  - Serum uric acid
EDAT- 2018/09/10 06:00
MHDA- 2019/02/20 06:00
CRDT- 2018/09/10 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/08/30 00:00 [accepted]
PHST- 2018/08/14 00:00 [revised]
PHST- 2018/09/10 06:00 [pubmed]
PHST- 2019/02/20 06:00 [medline]
PHST- 2018/09/10 06:00 [entrez]
AID - 10.1007/s10067-018-4283-z [pii]
AID - 10.1007/s10067-018-4283-z [doi]
PST - ppublish
SO  - Clin Rheumatol. 2018 Nov;37(11):3107-3113. doi: 10.1007/s10067-018-4283-z. Epub 
      2018 Sep 9.